Ülseratif kolitli hastalarda paraoksanaz 1 ve arilesteraz seviyeleri ve bu parametrelerin hastalık aktivitesi ile ilişkileri
Giriş ve Amaç: Bu çalışmada ülseratif kolitli hastalarda serum paraoksonaz 1 ve arilesteraz düzeyleri ve bu parametrelerin hastalık aktivitesi ile ilişkileri araştırıldı. Gereç ve Yöntem: Çalışmaya 38 aktif dönemde ülseratif kolit hastası ve 38 sağlıklı kontrol grubu hastası dahil edildi. Çalışma grubu hastalarından hem aktif dönemde hem de remisyon sağlanınca paraoksonaz 1 ve arilesteraz enzim aktiviteleri çalışıldı. Paraoksonaz 1 ve arilesteraz enzim aktiviteleri aktif dönem, remisyon dönemi ve kontrol grubu arasında kıyaslandı. Bulgular: Çalışma grubu hastalarının yaş ortalaması 40.3±14.6 yıl (19-78) olup hastaların 20’si erkek (%52.6) ve 18’i kadın (%47.4) idi. Kontrol grubu hastalarının demografik özellikleri çalışma grubuna benzerdi. Aktif dönemdeki ülseratif kolit hastalarının ortalama serum paraoksonaz 1 değeri 65.8±15.0 U/L, ortalama serum arilesteraz değeri ise 151.0±236.6 U/mL olarak tespit edildi. Remisyon dönemindeki hastalarda ortalama serum paraoksonaz 1 değeri 82.4±58.4 U/L, ortalama serum arilesteraz değeri ise 94.1±134.6 U/ mL olarak tespit edildi. Kontrol grubundaki hastalarda ortalama serum paraoksonaz 1 değeri 131.7±63.5 U/L, ortalama serum arilesteraz değeri ise 287.3±295.6 U/mL olarak tespit edildi. Ülseratif kolitli hastalarda ortalama paraoksonaz 1 ve arilesteraz düzeyleri aktif ve remisyon dönemi arasında istatistiksel olarak anlamlı fark göstermedi (p>0.05). Aktif ve remisyon dönemindeki ülseratif kolitli hastalarda ortalama paraoksonaz 1 ve arilesteraz değerleri kontrol grubundaki sağlıklı bireylere göre istatistiksel olarak anlamlı şekilde düşük bulundu (p
Paraoxonase 1 and arylesterase levels in patients with ulcerative colitis and their relationship with disease activity
Background and Aims: In this study, we studied serum paraoxanase 1 and arylesterase levels in patients with ulcerative colitis and their relationship with disease activity. Material and Methods: Thirty-eight patients with active ulcerative colitis and 38 healthy controls were included in this study. Paraoxanase 1 and arylesterase enzyme activities in both active and remission phases were studied. Paraoxanase 1 and arylesterase enzyme activities in the active disease phase, the remission phase, and the control group were compared. Results: The mean patient age in the study group was 40.3±14.6 years (19-78); 20 patients were male (52.6%) and 18 were female (47.4%). The demographic characteristics of the patients in the control group were similar to those of the study group. The mean serum paraoxanase 1 level was 65.8±15.0 U/L, and the mean serum arylesterase level was 151.0±236.6 U/mL in patients in the active phase. The mean serum paraoxanase 1 level was 82.4±58.4 U/L, and the mean serum arylesterase level was 94.1±134.6 U/mL in patients in the remission phase. The mean serum paraoxanase 1 level was 131.7±63.5 U/L, and the mean serum arylesterase level was 287.3±295.6 U/mL in the control group. There was no statistically significant difference in mean paraoxanase 1 and arylesterase levels between patients in the active and remission phases (p > 0.05). The mean levels of paraoxanase 1 and arylesterase in patients in the active and remission phases were significantly lower than those in healthy controls (p < 0.05). Conclusion: In patients with ulcerative colitis, paraoxanase 1 and arylesterase enzyme activities were found to be significantly lower than those in the control group, but there was no relationship between disease activity and paraoxanase 1 and arylesterase enzyme activities.
___
- Çavuşoğlu H, İliçin G, Ünal S, Biberoğlu K, Süleymanlar G. İnflamatuar
barsak hastalığı. İç Hastalıkları. 2. baskı. Ankara: Güneş
Kitabevi, 2003:1577-90.
- Tezel A. Etiopathogenesis of ulcerative colitis. Turkiye Klinikleri J
Gastroenterohepatol-Special Topics 2009;2:7-12.
- Fiocchi C. Future of IBD pathogenesis: How much work is left to
do? Inflamm Bowel Dis 2008;14(Suppl 2):S145-7.
- Friedman S, Blumberg RS. Inflammatory bowel disease. In; Braunwald
E, Fauci AS, Kasper DL, et al. (eds). Harrison’s Principles of Internal
Medicine. 16th ed. New York; McGraw-Hill. 2005;1776-89.
- Draganov DI, Teiber JF, Speelman A, et al. Human paraoxonases
(PON1, PON2, and PON3) are lactonases with overlapping and distinct
substrate specificities. J Lipid Res 2005;46:1239-47.
- Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase.
Gen Pharmacol 1998;31:329-36.
- Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase
(PON1) activity. Biochem Pharmacol 2005;69:541-50.
- Mackness B, McElduff P, Mackness MI. The paraoxonase-2-310
polymorphism is associated with the presence of microvascular
complications in diabetes mellitus. J Intern Med 2005;258:363-8.
- Baum L, Ng HK, Woo KS, et al. Paraoxonase 1 gene Q192R polymorphism
affects stroke and myocardial infarction risk. Clin Biochem
2006;39:191-5.
- Suchocka Z, Swatowska J, Pachecka J, Suchocki P. RP-HPLC determination
of paraoxonase activity in human blood serum. J Pharm
Biomed Anal 200611;42:113-9.
- Gokdemir MT, Karakilcik AZ, Gokdemir GS. Prognostic importance
of paraoxonase, arylesterase and mean platelet volume efficiency
in acute ischaemic stroke. J Pak Med Assoc 2017;67:1679-83.
- Utanğaç MM, Yeni E, Savaş M, et al. Paraoxonase and arylesterase
activity in bladder cancer. Turk J Urol 2017;43:147-51.
- Kul A, Uzkeser H, Ozturk N. Paraoxonase and arylesterase levels
in Behcet’s Disease and their relations with the disease activity.
Biochem Genet 2017;55:335-44.
- Trulove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report
on a therapeutic trial. Br Med J 1954;2:375-8.
- Isik A, Koca SS, Ustundag B, et al. Paraoxonase and arylesterase
levels in rheumatoid arthritis. Clin Rheumatol 2007;26:342-8.
- Kafadar AM, Ergen A, Zeybek U, et al. Paraoxonase 192 gene polymorphism
and serum para¬oxonase activity in high grade gliomas
and menegiomas. Cell Biochem Funct 2006;24:455-60.
- Yıldırım A, Aslan Ş, Ocak T, Yıldırım S, Kara F, Şahin YN. Serum
paraoxonase/arylesterase activities and malondialdehyde levels in
trauma patients. Eurasian J Med 2007;39:85-8.
- Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraox¬onase
levels in gastric cancer. Hepatogastroenterology 2003;50(Suppl
2):cclxxiii-cclxxv.
- Akçay MN, Polat MF, Yilmaz I, Akçay G. Serum paraoxonase levels
in pancreatic cancer. Hepatogastroenterology 2003;50(Suppl
2):ccxxv-ccxxvii.
- Elkiran ET, Mar N, Aygen B, et al. Serum paraoxonase and arylesterase
activities in patients with lung cancer in a Turkish population.
BMC Cancer 2007;15:48.
- Başkol G, Başkol M, Yurci A, et al. Serum paraoxonase 1 activity
and malondialdehyde levels in patients with ulcerative colitis. Cell
Biochem Funct 2006;24:283-6.
- D’Inca R, Cardin R, Benazzato L, et al. Oxidative DNA damage in
the mucosa of ulcerative colitis increases with disease duration and
dysplasia. Inflamm Bowel Dis 2004;10:23-7.
- Sturniolo GC, Mestriner C, Lecis PE, et al. Altered plasma and mucosal
concentrations of trace elements and antioxidants in active
ulcerative colitis. Scand J Gastroenterol 1998;33:644-9.
- Ferretti G, Bacchetti T, Moroni C, et al. Copper-induced oxidative
damageon astrocytes: protective effect exerted by human high
density lipoproteins. Biochimica Biophysica Acta 2003;1635:48-54.
- Rothem L, Hartman C, Dahan A, et al. Paraoxonases are associated
with intestinal inflammatory diseases and intracellularly localized to
the endoplasmic reticulum. Free Radic Biol Med 2007;43:730-9.
- Boehm D, Krzystek-Korpacka M, Neubauer K, et al. Paraoxonase-1status
in Crohn’s disease and ulcerative colitis. Inflamm Bowel
Dis 2009;15:93-9.
- Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress,
and macrophage foam cell formation during atherosclerosis development.
Free Radic Biol Med 2004;37:1304-16.
- Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity
predicts coronaryevents in the Caerphilly Prospective Study.
Circulation 2003;107:2775-9.
- Nakamura M, Saito H, Kasanuki J, et al. Cytokine production in
patients with inflammatory bowel disease. Gut 1992;33:933-7.
- Olson AD, Ayass M, Chensue S. Tumor necrosis factor and IL-1 beta
expression in pediatric patients with inflammatory bowel disease. J
Pediatr Gastroenterol Nutr 1993;16:241-6.
- Funakoshi K, Sugimura K, Sasakawa T, et al. Study of cytokines in
ulcerative colitis. J Gastroenterol 1995;30(Suppl 8):61-3.
- Kumon Y, Nakauchi Y, Suehiro T, et al. Proinflammatory cytokines
but not acute phase serum amyloid A or C-reactive protein, downregulate
paraoxonase 1 (PON1) expression by Hep G2 cells. Amyloid
2002;9:160-4.
- Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL
becomes pro-inflammatory during the acute phase response. Loss
of protective effect of HDL against LDL oxidation in aortic wall cell
cocultures. J Clin Invest 1995;96:2758-67.